Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kristen Cowens"'
Autor:
Kimberly J. Hassett, Ivana Liric Rajlic, Kapil Bahl, Rebecca White, Kristen Cowens, Eric Jacquinet, Kristine E. Burke
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 1, Pp 102083- (2024)
The mRNA vaccine route from injection site to critical immunologic tissues, as well as the localization of protein antigen following intramuscular (i.m.) administration, is crucial to generating an effective immune response. Here, we quantified mRNA
Externí odkaz:
https://doaj.org/article/331caee5d19e413694e12ac4eabff659
Autor:
Karen McKinnon, Kristen Cowens, Dante Bortone, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A Cuaboy, Amy L Garrett, Benjamin C Calhoun, Alec D Wilkinson, E Claire Dees, Benjamin G Vincent, Jonathan S Serody
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/4b4477f689454bc2b5fe6bd317c412e0
Autor:
Benjamin Vincent, Dominic Moore, Mark Woodcock, Carey Anders, Amanda Van Swearingen, Maria Sambade, Luz Cuaboy, Amy Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin Calhoun, Lisa Carey, Claire Dees, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, Jonathan Serody
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/66ceae14360c4fa2897157a5c2f6fcac
Autor:
James D. Griffin, Marion Wiesmann, Sean M. McDonough, Jens U. Wuerthner, Sebastien Jeay, Martin Sattler, Erik Nelson, Kristen Cowens, Ilene Galinsky, Richard Stone, Moriko Ito, Louise Barys, Brandon Antonakos, Jing Yuan, Irene Simkin, Takaomi Sanda, Tao Ren, Atsushi Nonami, Vesselina G. Cooke, Ensar Halilovic, Ellen Weisberg
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77652698c8f5e96ead4e624b606e372c
https://doi.org/10.1158/1535-7163.22506793
https://doi.org/10.1158/1535-7163.22506793
Autor:
James D. Griffin, Marion Wiesmann, Sean M. McDonough, Jens U. Wuerthner, Sebastien Jeay, Martin Sattler, Erik Nelson, Kristen Cowens, Ilene Galinsky, Richard Stone, Moriko Ito, Louise Barys, Brandon Antonakos, Jing Yuan, Irene Simkin, Takaomi Sanda, Tao Ren, Atsushi Nonami, Vesselina G. Cooke, Ensar Halilovic, Ellen Weisberg
Supplementary Table III: AML patient samples tested with HDM2 inhibitor, CGM097: IC50 values for CGM097.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03d9f78b11fd339b51f82e9097596b5f
https://doi.org/10.1158/1535-7163.22506781.v1
https://doi.org/10.1158/1535-7163.22506781.v1
Autor:
James D. Griffin, Marion Wiesmann, Sean M. McDonough, Jens U. Wuerthner, Sebastien Jeay, Martin Sattler, Erik Nelson, Kristen Cowens, Ilene Galinsky, Richard Stone, Moriko Ito, Louise Barys, Brandon Antonakos, Jing Yuan, Irene Simkin, Takaomi Sanda, Tao Ren, Atsushi Nonami, Vesselina G. Cooke, Ensar Halilovic, Ellen Weisberg
The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type (WT) p53, the HDM2 protein binds to p53 and block
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a202bb70fbbf98f1078a1bda4271a89
https://doi.org/10.1158/1535-7163.c.6538492.v1
https://doi.org/10.1158/1535-7163.c.6538492.v1
Autor:
James D. Griffin, Marion Wiesmann, Sean M. McDonough, Jens U. Wuerthner, Sebastien Jeay, Martin Sattler, Erik Nelson, Kristen Cowens, Ilene Galinsky, Richard Stone, Moriko Ito, Louise Barys, Brandon Antonakos, Jing Yuan, Irene Simkin, Takaomi Sanda, Tao Ren, Atsushi Nonami, Vesselina G. Cooke, Ensar Halilovic, Ellen Weisberg
Supplementary Figures 1-7 Supplementary Figure 1. Amplification and sequencing primers used for genotyping of p53 in AML patient samples. Supplementary Figure 2. Apoptosis data corresponding to representative bar graphs shown in Figure 1C. Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c85fda8083880149c6582ea722cbd30
https://doi.org/10.1158/1535-7163.22506790
https://doi.org/10.1158/1535-7163.22506790
Autor:
Trevor A. Jolly, Rachel C. Jankowitz, Hyman B. Muss, Claire Dees, Dominic T. Moore, Oludamilola Olajide, Maria J. Sambade, KE Reeder-Hayes, Rebecca Kaltman, Luz Cuaboy, CM Perou, Kristen Cowens, Carey K. Anders, Lisa A. Carey, J.S. Serody, Dante S. Bortone, Mark Woodcock, Benjamin C. Calhoun, Amy Garrett, Benjamin G. Vincent, Karen P. McKinnon, Vinay K. Gudena
Publikováno v:
Cancer Research. 79:P2-09
Background: While immunotherapy holds promise in the treatment of mTNBC, response rates (RR) in unselected patients (pts) are approximately 20%. Strategies to augment response to immunotherapy include depletion of regulatory T cells (Tregs). A single
Autor:
Charles M. Perou, Katherine E. Reeder-Hayes, Oludamilola Olajide, Hyman B. Muss, Claire Dees, Dante S. Bortone, Amanda E.D. Van Swearingen, Amy Garrett, Rachel C. Jankowitz, Dominic T. Moore, Carey K. Anders, Maria J. Sambade, Mark Woodcock, Karen P. McKinnon, Luz Cuaboy, Rebecca Kaltman, Benjamin G. Vincent, Benjamin C. Calhoun, Kristen Cowens, Lisa A. Carey, Vinay K. Gudena, Trevor A. Jolly, Jonathan S. Serody
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background In metastatic triple negative breast cancer (mTNBC), median progression-free survival (PFS) with chemotherapy alone is approximately 2–4 months1 and improvements with single agent checkpoint inhibitors (CI) are limited by modest response
Autor:
Meghan E. Free, Simon Mallal, William W. Kwok, Kristen Cowens, Benjamin G. Vincent, Mark A. Pilkinton, Olivier M. Lardinois, Eddie A. James, Dante S. Bortone, Susan L. Hogan, Ronald J. Falk, Elizabeth A. McInnis, John Sidney, Bjoern Peters, J. Charles Jennette, Jacob J. Hess, Dominic Ciavatta, Carmen E. Mendoza, Alex J. Guseman, Andrew K. Le, Yichun Hu, Katherine G. Stember, Edita Karosiene
Publikováno v:
J Autoimmun
Background Treatment of autoimmune diseases has relied on broad immunosuppression. Knowledge of specific interactions between human leukocyte antigen (HLA), the autoantigen, and effector immune cells, provides the foundation for antigen-specific ther